Antibodies Journal
Explore evitria’s Antibody Journal for in-depth articles on antibody engineering, CHO cell expression systems, and advancements in recombinant antibody production services.
Articles about Antibodies Journal (2)
-
Bengt Thorsson and Johan Rockberg to join Atlas Antibodies’ Board of Directors
We are pleased to announce the election of Bengt Thorsson and Johan Rockberg to Atlas Antibodies’ Board of Directors, following the AGM on May 23, 2025. Åsa Riisberg has been re-elected as Chair of the Board and Catarina Flyborg, Gavin Wood, Christian Eberle and Louise Kores have been re-elected as board members. We thank Mathias […]
-
Press release: evitria Celebrates 15 Years with Exclusive Giveaway for Industry Experts
Tickets for Festival of Biologics, Networking Dinner, and Exclusive Tour of evitria AG in Zürich Up for Grabs Zurich, Switzerland – March 2025 – evitria, a leading provider of antibody development services, is celebrating its 15th anniversary with an exciting giveaway that offers an exclusive opportunity to attend the Festival of Biologics in Basel, Switzerland. […]
-
HEK293 cells for recombinant antibody production
HEK cells are intensely used in applications like recombinant antibody production. Why? Find out in this article!
-
Engineering bispecific antibodies
Recorded Presentation: From mAb to bAb Developing drugs requires navigating complex technical, practical, and strategic challenges quickly. Optimizing a drug’s activity and effectiveness and subsequently considering the IP landscape are crucially important balancing acts. Here, we demonstrate how evitria’s extensive expertise in antibody production can help you engineer, reformat, and produce your therapeutic, using a […]
-
7 reasons for us to choose Chinese hamster ovary (CHO) cells for recombinant protein production
In this article, we will discuss 7 reasons why we at evitria use CHO cells in recombinant protein production.
-
evitria and Lonza Sign License Agreement to Provide Fast Access to bYlok® Bispecific Antibodies for Discovery-Stage Transient Expression Research
Zurich-based evitria AG has entered a non-exclusive license agreement with Lonza for its bYlok® technology, enabling simple and reliable development of IgG-like bispecific antibodies.
-
Therapeutic antibodies: afucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC)
Therapeutic antibodies are the fastest-growing class of biological drugs. Their ability to interact with specific targets means they can be employed for a range of diseases, including cancer, autoimmune and infectious diseases.
-
Transient transfection vs. stable transfection
Both transient and stable transfection are essential methods in genetic engineering. But what are the differences between them? Let’s find out in this article.
-
Benefits of transient transfection
Transient transfection offers numerous advantages in the expression of recombinant proteins. We will uncover the main benefits in this article.
-
How are afucosylated antibodies developed?
Afucosylated antibodies are promising tools in the fight against several diseases. But how are they developed? That is what we are going to find out in this article.
-
Applications of afucosylated antibodies
Afucosylated antibodies are either studied or already used in various fields of application. In this article, we will explore some of them.
-
What is antibody discovery?
Antibody discovery is a key phase in the development of new therapeutic and diagnostic tools. In this article, we will shed light on this process.